Combining both BL and FP conditions, we concluded that compared with ERBB2 copy number or TCL, plasma TMB was a better option to predict and dynamically surveillant the therapeutic outputs of HER2‐targeted therapy in GC. The gene discussed is ERBB2; the disease is gastric cancer.